GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (LTS:0JQ2) » Definitions » Short Interest

Kala Bio (LTS:0JQ2) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Kala Bio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Kala Bio's Short Interest

For the Biotechnology subindustry, Kala Bio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kala Bio's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's Short Interest distribution charts can be found below:

* The bar in red indicates where Kala Bio's Short Interest falls into.


Kala Bio (LTS:0JQ2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (LTS:0JQ2) » Definitions » Short Interest
Comparable Companies
AVTX FRES FBRX TCRT EQ PMCB NTRB LSTA TFFP COCP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KALA:USA 27F0:Germany
Address
1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Website
https://www.kalarx.com
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio (LTS:0JQ2) Headlines

No Headlines